.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Chikungunya virus (CHIKV) continues to pose a severe public health challenge globally, including in India. Currently, no specific vaccine or Chikungunya antiviral treatment exists for clinical use. Researchers are therefore investigating novel synthetic compounds to fill this therapeutic gap. A recent study has highlighted bis-naphthoquinone (H-5) as a particularly promising candidate due to its high efficacy and safety profile.
The investigation utilized various cellular and animal models to evaluate the potency of H-5. Laboratory tests revealed that the compound has a low cytotoxicity (CC50) of 1103 μM. Meanwhile, its antiviral activity (EC50) reached a significant level of 0.96 μM. Consequently, H-5 demonstrates a wide therapeutic window. Furthermore, time-of-addition experiments confirmed that the drug effectively inhibits the viral replication cycle. Additionally, the study explored combination therapy. Results showed a strong synergistic effect when researchers combined H-5 with Ribavirin. This interaction could potentially lead to more effective clinical outcomes using lower drug dosages.
Beyond laboratory cultures, H-5 showed considerable potential in mouse models. The compound significantly reduced edema and induced favorable histological changes in infected tissues. Therefore, these findings suggest that H-5 is a robust candidate for a Chikungunya antiviral treatment. Nevertheless, further clinical trials are necessary to confirm these results in human patients. Medical professionals should monitor these developments closely, as they represent a major advancement in managing arboviral infections.
Currently, there is no specific antiviral treatment for Chikungunya. H-5 is a novel synthetic compound that specifically targets viral replication with high potency and low toxicity, unlike current symptomatic care.
The strong synergistic effect suggests that combining H-5 with Ribavirin can enhance antiviral efficacy. This synergy potentially allows for lower therapeutic doses and reduced side effects in future treatment regimens.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Clinical decisions should be made by qualified healthcare professionals. Refer to the latest local and national guidelines for clinical practice.
References
Gomes MWL et al. Antiviral Activity of Synthetic Bis-Naphthoquinone (H-5) against Chikungunya Virus Replication. Curr Top Med Chem. 2026 Apr 06. doi: 10.2174/0115680266358458251009100413. PMID: 41944112.
World Health Organization. Chikungunya Fact Sheet. 2023.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Study reveals the high antiviral potential of synthetic bis-naphthoquinone (H-5) against Chikungunya, showing low toxicity and synergistic effects....
5 months ago
A comparative analysis shows that older age, elevated blood glucose, and abdominal adiposity are primary drivers of hypertension. Comprehensive evaluation of cardiometabolic risk profiles enables clinicians to detect overlapping metabolic dysfunctions early and optimize targeted prevention strategies.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Left ventricular thrombus is a severe complication of acute decompensated heart failure. This clinical review explores the pathophysiology, imaging challenges, and pharmacotherapeutic considerations of laminated thrombi, evaluating the evolving role of direct oral anticoagulants versus traditional warfarin.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
